-+ 0.00%
-+ 0.00%
-+ 0.00%
Novo Nordisk Outlines Semaglutide, CagriSema Trial Results
Share
Listen to the news
07:52 AM EST, 11/15/2026 (MT Newswires) -- Novo Nordisk (NOVO-B.CO) said Nov. 14 that clinical trial results showed food noise reductions from semaglutide and weight loss from lower doses of CagriSema. The Signal and Octane studies found both the oral and injectable semaglutide to be linked to early reductions in food noise in real-world studies, the Danish pharmaceutical company added. Additionally, primary results from the phase 3 Redefine 9 trial of CagriSema showed that 1.7 milligrams and 1 mg of the investigational drug led to average weight loss of 20.7% and 21.0%, respectively, at 68 weeks, compared with 2.0% with placebo, in adults with overweight or obesity.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending